[Combination therapy based on PD-1/PD-L1 blocking in the treatment of non-small cell lung cancer]

Ningning Zhang,Xu Wang,Jinao Shen,Shiyu Sun,Yan Shen,Jun Wang

Abstract:Non-small cell lung cancer (NSCLC) is one of the most serious malignancies and a serious threat to patients' quality of life. Traditional treatment have limitations such as side-effects, recurrence, drug resistance and lack of specificity. A novel therapy with immune checkpoint blocking has marked a breakthrough in the field of tumor therapy. It transforms the target of tumor therapy from a single molecule to immune cells, and provides a new strategy with a focus on the regulation of T cell function to control tumor progression. Programmed death 1 (PD-1) is the most well-studied immune checkpoint molecules. In recent years, profound progress was made in developing immunotherapies targeting the PD-1/PD-L1 signaling pathway, particularly in the treatment of NSCLC, given their high specificity and low side-effects. Nevertheless, there are still a considerable number of patients who have no significant therapeutic effect after receiving single antibodies that block the PD-1/PD-L1 pathway. Studies have shown that immunotherapy targeting the PD-1/PD-L1 pathway in the combination with other therapies can significantly improve survival rate and quality of life in patients. Such as radiotherapy and chemotherapy, dual immune checkpoint intervention, immunomodulator intervention, and even intestinal flora regulation can also be combined with anti-PD-1 /PD-L1 antibody for clinical treatment of NSCLC. These combination therapies have their own strengths and limitations, and their synergy mechanism requires further study. For NSCLC, more potential combined therapies based on PD-1/PD-L1 blockade are also being explored, laying a foundation for improving the survival rate and quality of life of NSCLC patients.